KR102220260B1 - 스트레스-유도성 p-tau 를 낮추는 트리아졸로피리딘 및 트리아졸로피리미딘 - Google Patents

스트레스-유도성 p-tau 를 낮추는 트리아졸로피리딘 및 트리아졸로피리미딘 Download PDF

Info

Publication number
KR102220260B1
KR102220260B1 KR1020177025850A KR20177025850A KR102220260B1 KR 102220260 B1 KR102220260 B1 KR 102220260B1 KR 1020177025850 A KR1020177025850 A KR 1020177025850A KR 20177025850 A KR20177025850 A KR 20177025850A KR 102220260 B1 KR102220260 B1 KR 102220260B1
Authority
KR
South Korea
Prior art keywords
delete delete
tau
alzheimer
disease
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177025850A
Other languages
English (en)
Korean (ko)
Other versions
KR20170117185A (ko
Inventor
바게스 존
데일 이 브레데슨
Original Assignee
버크 인스티튜트 포 리서치 온 에이징
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 버크 인스티튜트 포 리서치 온 에이징 filed Critical 버크 인스티튜트 포 리서치 온 에이징
Publication of KR20170117185A publication Critical patent/KR20170117185A/ko
Application granted granted Critical
Publication of KR102220260B1 publication Critical patent/KR102220260B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020177025850A 2015-02-18 2016-02-17 스트레스-유도성 p-tau 를 낮추는 트리아졸로피리딘 및 트리아졸로피리미딘 Active KR102220260B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562117888P 2015-02-18 2015-02-18
US62/117,888 2015-02-18
PCT/US2016/018305 WO2016134042A2 (en) 2015-02-18 2016-02-17 Triazolopyridines and triazolopyrimidines that lower stress-induced p-tau

Publications (2)

Publication Number Publication Date
KR20170117185A KR20170117185A (ko) 2017-10-20
KR102220260B1 true KR102220260B1 (ko) 2021-02-25

Family

ID=56692299

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177025850A Active KR102220260B1 (ko) 2015-02-18 2016-02-17 스트레스-유도성 p-tau 를 낮추는 트리아졸로피리딘 및 트리아졸로피리미딘

Country Status (8)

Country Link
US (2) US10618899B2 (https=)
EP (1) EP3259274B1 (https=)
JP (1) JP6830895B2 (https=)
KR (1) KR102220260B1 (https=)
CN (1) CN107709326B (https=)
AU (1) AU2016220049C1 (https=)
CA (1) CA2976258C (https=)
WO (1) WO2016134042A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102220260B1 (ko) 2015-02-18 2021-02-25 버크 인스티튜트 포 리서치 온 에이징 스트레스-유도성 p-tau 를 낮추는 트리아졸로피리딘 및 트리아졸로피리미딘
EP3969639B1 (en) 2019-05-13 2025-03-12 Ecolab Usa Inc. 1,2,4-triazolo[1,5-a] pyrimidine derivative as copper corrosion inhibitor
ES2932481B2 (es) * 2021-07-09 2023-09-11 Consejo Superior Investigacion Compuestos inhibidores de la quinasa de tau y tubulina (ttbk)

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL313973A1 (en) 1993-10-12 1996-08-05 Du Pont Merck Pharma 1 n-alkyl-n-arylopyrimidin amines and their derivatives
US6107300A (en) * 1996-03-27 2000-08-22 Dupont Pharmaceuticals Arylamino fused pyrimidines
EP1012151B1 (en) * 1997-09-02 2002-08-07 Bristol-Myers Squibb Pharma Company Heterocyclyl-substituted ring-fused pyridines and pyrimidines as corticotropin releasing hormone (crh) antagonists, useful for treating cns and stress-related disorders
CA2398956A1 (en) 2000-02-14 2001-08-16 Japan Tobacco Inc. A pharmaceutical composition for prophylaxis or therapy of a postoperative stress
WO2004037159A2 (en) 2002-10-23 2004-05-06 Obetherapy Biotechnology Compounds, compositions and methods for modulating fat metabolism
WO2007076055A2 (en) 2005-12-22 2007-07-05 Entremed, Inc. Compositions and methods comprising proteinase activated receptor antagonists
JP6250394B2 (ja) 2010-08-19 2017-12-20 バック・インスティテュート・フォー・リサーチ・オン・エイジング 軽度の認知障害（ｍｃｉ）および関連障害の処置方法
US11325904B2 (en) 2011-08-02 2022-05-10 Buck Institute For Research On Aging Tropinol esters and related compounds to promote normal processing of APP
WO2013026021A2 (en) 2011-08-18 2013-02-21 Buck Institute For Research On Aging Trka as a target for inhibiting app cleavage and/or progression of alzheimer's disease
AU2013235422B2 (en) 2012-03-19 2016-12-15 Buck Institute For Research On Aging APP specific BACE inhibitors (ASBIs) and uses thereof
EP2903436B1 (en) * 2012-09-19 2019-07-17 The Trustees Of The University Of Pennsylvania Heterocyclic compounds and their use for the treatment of neurodegenerative tauopathies
US20140371283A1 (en) 2013-02-12 2014-12-18 Buck Institute For Research On Aging Hydantoins that modulate bace-mediated app processing
KR102220260B1 (ko) 2015-02-18 2021-02-25 버크 인스티튜트 포 리서치 온 에이징 스트레스-유도성 p-tau 를 낮추는 트리아졸로피리딘 및 트리아졸로피리미딘

Also Published As

Publication number Publication date
US20180346466A1 (en) 2018-12-06
AU2016220049A1 (en) 2017-08-24
EP3259274A4 (en) 2018-08-01
US10618899B2 (en) 2020-04-14
WO2016134042A2 (en) 2016-08-25
CA2976258A1 (en) 2016-08-25
CN107709326B (zh) 2021-12-17
EP3259274A2 (en) 2017-12-27
AU2016220049C1 (en) 2021-02-25
AU2016220049B2 (en) 2020-09-24
US10844071B2 (en) 2020-11-24
WO2016134042A3 (en) 2016-10-13
JP6830895B2 (ja) 2021-02-17
KR20170117185A (ko) 2017-10-20
EP3259274B1 (en) 2023-06-28
CN107709326A (zh) 2018-02-16
US20200190094A1 (en) 2020-06-18
CA2976258C (en) 2024-02-20
JP2018505899A (ja) 2018-03-01

Similar Documents

Publication Publication Date Title
US11091444B2 (en) Hydantoins that modulate BACE-mediated app processing
US10844071B2 (en) Substituted [1,2,3]triazolo[4,5-d]pyrimidines that lower stress-induced p-tau
EP3183229A1 (en) Apoe4-targeted theraputics that increase sirt1

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20170913

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20190215

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20200720

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20201120

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20200720

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20201120

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20200918

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20190215

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20210111

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20201222

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20201120

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20200918

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20190215

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20210219

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20210219

End annual number: 3

Start annual number: 1

PG1601 Publication of registration